Cemiplimab (Libtayo, Regeneron Pharmaceuticals ... FRACP, research lead of head and neck cancer and cutaneous squamous cell carcinoma in the department of medical oncology at Peter MacCallum ...
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab ... M.B.B.S., F.R.A.C.P., ...
This randomized trial evaluates the clinical activity and safety of BNT111 in combination with the anti-PD-1 antibody cemiplimab. The results from this trial underscore the potential of mRNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback